Market Overview

ImmusanT to Present New Nexvax2® Dosing Data at United European Gastroenterology (UEG) Week

Share:

ImmusanT,
Inc.
, a clinical-stage company developing Nexvax2®, a therapeutic
vaccine being investigated to assess the effects of gluten in HLA-DQ2.5+
patients with celiac disease, today announced it will present data on
Nexvax2® dosing at United European Gastrointestinal (UEG)
Week, occurring October 28-November 1, 2017 in Barcelona, Spain. The
data, presented via two oral presentations, will assess the safety and
tolerability of Nexvax2® at various dose levels and changes
in circulating cytokines in celiac disease volunteers on a gluten-free
diet after eating gluten or after intradermal administration of Nexvax2®.

Details of the presentations are as follows:

Date: Monday, October 30
Time: 14:12-14:24 CET
Location:
Room B2
Session: Celiac disease and wheat-related disorder
Abstract
Number:
OP060
Title: Gluten ingestion and intradermal
injection of peptides that activate gluten-specific CD4+ T cells elicit
a cytokine signature dominated by interleukin-2 in celiac disease

Date: Monday, October 30
Time: 16:57-17:09 CET
Location:
Room E2
Session: Gluten-related disorders
Abstract
Number:
OP118
Title: Safety and tolerability,
immunological and intestinal effects, and pharmacokinetics (PK) of dose
titration preceding maintenance doses of Nexvax2® in HLA-DQ2.5+ celiac
disease (CeD)

About Celiac Disease

Celiac disease is a T cell-mediated autoimmune gastrointestinal disease
triggered by the ingestion of gluten from wheat, rye and barley
predominantly in individuals who carry the human leukocyte antigen-DQ2.5
(HLA-DQ2.5) immune recognition gene. A gluten-free diet is the only
current management for this disease. The community prevalence of celiac
disease is approximately 1% in the U.S., but over 80% of cases go
unrecognized. When a person with celiac disease consumes gluten, the
individual's immune system responds by triggering T cells to fight the
offending proteins, damaging the small intestine and inhibiting the
absorption of important nutrients into the body. Undiagnosed, celiac
disease is a major contributor to poor educational performance and
failure to thrive in children. Untreated disease in adults is associated
with osteoporosis and increased risk of fractures, anemia, reduced
fertility, problems during pregnancy and birth, short stature, dental
enamel hypoplasia, dermatitis, recurrent stomatitis and cancer. With no
available drug therapy, the only option is a strict and lifelong
elimination of gluten from the diet. Compliance is often challenging,
and the majority of people continue to have residual damage to their
small intestine in spite of adherence to a gluten-free diet.

About Nexvax2®

Nexvax2® is the only therapeutic approach for celiac disease in clinical
development today that targets the fundamental cause of the disease,
that is the loss of immune tolerance to gluten. Nexvax2® is a
combination of three proprietary peptides that is delivered by injection
as a therapeutic vaccine and reprograms the T-cells that respond to
gluten antigens in celiac disease patients so that they stop triggering
a pro-inflammatory response. By increasing the threshold for clinical
reactivity to natural exposure to gluten, Nexvax2® is intended to
protect patients with celiac disease against inadvertent exposure to
gluten and ultimately restore immunological and clinical tolerance to
gluten.

About ImmusanT, Inc.

ImmusanT is a privately held biotechnology company focused on protecting
patients with celiac disease against the effects of gluten. By
harnessing new discoveries in immunology, ImmusanT aims to improve
diagnosis and medical management of celiac disease by protecting against
the effects of gluten exposure while patients maintain a gluten-free
diet. The company is developing Nexvax2®,
a therapeutic vaccine for celiac disease, and diagnostic and monitoring
tools to improve celiac disease management. ImmusanT's targeted
immunotherapy discovery platform can be applied to a variety of
autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera
Healthcare Partners
. More information may be found at www.ImmusanT.com,
or follow ImmusanT
on Twitter.

View Comments and Join the Discussion!